Highlight

1. ClearMOA

1) Monoamine oxidase-B (MAOB) is an enzyme in the body that breaks down several chemicals in the brain, including DA.

2) An MAOB inhibitor makes more DA available to the brain. When used with other medications, It can improve many PD movement symptoms and reduce motor fluctuations-minimizing off time and extending on time.

2.High selectivity and inhibitory activity.

3.Potential global first “Forth-generation MAOB inhibitor”.

4.Better treatment effect for PD than Safinamidein preclinical.

1) pre-MPTP administration: Improve the physical activity of mice, increase the concentration of DA in striatum, and protect dopaminergic neurons in substantia nigra compacta.

2) post-MPTP administration: In combination with L-dopa/Bens, the concentration of DA in striatum is significantly increased and the therapeutic effect on PD is enhanced.

3) Low risk of heart disease, reduce the phenomenon of mandibular tremor induced by Galanthamine.

5. Excellent phase 1 data.

1) PK: Fast absorption, medium elimination speed, No Cmax and litter AUC accumulation after multiple administration.

2) Medication safety, well-tolerated, no AEs(CTCAE≥3), no sAEs.

Research progress：

1) Phase 1 trial is completed.

2) Safety, well-tolerated, no AEs(CTCAE≥3), no sAEs.